Kura Oncology affiliate may sell up to 4,345 shares

Kura Oncology, Inc. (KURA) had an affiliate, Brian T. Powl, file a notice of proposed sale of company stock under Rule 144.

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) had an affiliate, Brian T. Powl, file a notice of proposed sale of company stock under Rule 144. The notice covers the potential sale of 4,345 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated value of approximately $50,879.95.

The shares were acquired upon the vesting of restricted stock units during the period from 01/26/2025 through 01/26/2026. The notice lists NASDAQ as the trading market and is dated 08/21/2026.

Key Figures

Shares proposed to be sold: 4,345 shares Aggregate market value: $50,879.95 Acquisition period for RSU vesting: 01/26/2025–01/26/2026 +1 more

4 metrics

Shares proposed to be sold 4,345 shares Common stock covered by the Rule 144 notice for Brian T. Powl

Aggregate market value $50,879.95 Indicated value of 4,345 Kura Oncology common shares in the notice

Acquisition period for RSU vesting 01/26/2025–01/26/2026 Period during which restricted stock units vested and yielded the shares

Notice date 08/21/2026 Date of the Rule 144 notice signed by Brian T. Powl

Key Terms

Rule 144, Restricted Stock Units, Form 144

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"The securities to be sold were acquired upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filed in August 2026 mean for KURA shareholders?

The Form 144 notifies of a proposed sale of 4,345 Kura Oncology (KURA) shares by Brian T. Powl under Rule 144, with an indicated value of about $50,879.95. It is a regulatory notice of possible sales, not a confirmation that the sale has occurred.

How many KURA shares are covered by Brian T. Powl’s Form 144 notice?

The notice covers up to 4,345 shares of Kura Oncology, Inc. common stock. These shares are proposed for sale under Rule 144 and are to be sold through Morgan Stanley Smith Barney LLC.

What is the approximate value of the KURA shares in this Form 144 filing?

The filing lists an aggregate value of approximately $50,879.95 for the 4,345 Kura Oncology (KURA) shares that may be sold under Rule 144.

How were the KURA shares in Brian T. Powl’s Form 144 acquired?

The shares were acquired upon the vesting of restricted stock units during the period from 01/26/2025 through 01/26/2026, as stated in the remarks section of the notice.

Which broker is named for the potential sale of KURA shares in this Form 144?

The notice identifies Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as the broker for the proposed sale of Kura Oncology (KURA) shares.

On which market are the KURA shares in this Form 144 expected to trade?

The Form 144 indicates that the Kura Oncology, Inc. common stock covered by the notice is to be sold on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:41 PM Accepted by SEC EDGAR 08/21/2026 - 04:41 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001934232
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KURA ONCOLOGY INC
SEC File Number	001-37620
Address of Issuer	4930 Directors Place, Suite 500 San Diego CALIFORNIA 92121
Phone	8585008800
Name of Person for Whose Account the Securities are To Be Sold	BRIAN POWL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4345	50879.95	88960619	08/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/26/2025	Restricted Stock Units	Issuer			4345	01/26/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 01/26/2025 through 01/26/2026.
Date of Notice	08/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Brian T. Powl
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)